US Justice Department Proposes Historic Reclassification of Marijuana

Regulations by 2FIRSTS.ai
May.17.2024
US Justice Department Proposes Historic Reclassification of Marijuana
U.S. Justice Department proposes historic reclassification of marijuana as safer drug, prompting potential benefits for research and cannabis industry.

According to a report by Reuters on May 17, the U.S. Department of Justice officially proposed a historic measure on Thursday (16th) to reclassify marijuana as a safer drug, stating that the risk of marijuana abuse is lower compared to other higher risk substances. If this regulation is enacted, it will also help facilitate further research on the medical benefits of marijuana.

 

The proposal states, "Furthermore, the FDA's review did not find any safety issues, indicating that the medical use of marijuana does not pose unacceptable high safety risks.

 

The Drug Enforcement Administration (DEA) in the United States is currently soliciting public feedback on the proposal, a process that may take some time, but Attorney General Merrick Garland has already given his approval. If approved, this new regulation would remove marijuana from the list of Schedule I drugs (which includes heroin, LSD, etc.) and reclassify it as a Schedule III drug, on par with ketamine and some synthetic steroids.

 

The department conducted a classification review of marijuana at the request of President Joe Biden in 2022. Additionally, Biden has taken steps to pardon thousands of individuals who were sentenced at the federal level for possession of marijuana, and has urged governors and mayors to take similar actions to commute these sentences. He hopes that this move will increase support for the Democratic party in an election year, especially among younger voters. Biden has promised, "Too many lives have been put in jeopardy due to the mishandling of marijuana, and I am committed to correcting these mistakes. You can trust my word."

 

Previously, the Assistant Secretary for Health at the U.S. Department of Health and Human Services (HHS) had recommended in August 2023 that the DEA classify marijuana as a Schedule III drug. The DEA has yet to make a specific classification for marijuana.

 

If the federal government relaxes marijuana classification, marijuana companies stand to benefit, such as being eligible to list on major stock exchanges and receive more generous tax breaks. Additionally, the banking restrictions they face may be reduced. Because marijuana is illegal at the federal level, most American banks do not provide loans or services to marijuana companies, prompting many banks to rely on cash transactions.

 

The public will have 60 days to submit comments on the proposal from the Department of Justice, and can also request a public hearing to be held on the proposal.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

69% of Russians Support Full Ban on E-Cigarette Sales, SuperJob Survey Shows
69% of Russians Support Full Ban on E-Cigarette Sales, SuperJob Survey Shows
According to Gazeta.Ru, a SuperJob poll found that 69% of Russians support President Vladimir Putin’s decision to fully ban vape sales in Russia. Only 7% oppose the ban, while 15% said they are indifferent and 9% were undecided.
Nov.10 by 2FIRSTS.ai
Wales Passes Law Banning Tobacco Sales to Anyone Born After 2009
Wales Passes Law Banning Tobacco Sales to Anyone Born After 2009
The Welsh Parliament (Senedd) has approved new legislation banning tobacco sales to anyone born on or after January 1, 2009. The law, passed on December 9, 2025, also imposes stricter controls on how vapes and nicotine products are advertised and sold. Designed by the UK Government but voted on separately in Wales, the bill passed with 36 votes in favor, two abstentions, and nine against. It grants stronger enforcement powers to Trading Standards to combat illegal tobacco and vape sales.
Dec.10 by 2FIRSTS.ai
Nicotine Pouch Brand VELO and McLaren Unveil Special Livery for the Abu Dhabi Grand Prix
Nicotine Pouch Brand VELO and McLaren Unveil Special Livery for the Abu Dhabi Grand Prix
According to PRNewswire, VELO and the McLaren Formula 1 Team have unveiled a special livery for the Abu Dhabi Grand Prix, co-created by nine superfans from around the world. The design forms the highlight of the “Live Your Fandom” campaign, reflecting memorable fan stories and celebrating the global McLaren community.
Dec.04 by 2FIRSTS.ai
PMI Extends Ferrari Partnership to 2026, Bringing ZYN Nicotine Pouches to F1
PMI Extends Ferrari Partnership to 2026, Bringing ZYN Nicotine Pouches to F1
Philip Morris International (PMI) has announced that it will extend its partnerships with Scuderia Ferrari HP and the Ferrari Challenge through the 2026 season and beyond, with its smoke-free nicotine pouch brand ZYN set to appear on Ferrari’s F1 livery for the first time from the 2025 Abu Dhabi Grand Prix. The company estimates that, as of June 30, 2025, more than 41 million adult consumers were using its smoke-free products worldwide.
Dec.04 by 2FIRSTS.ai
South Korea Implements Public Tobacco Harmfulness Management Program, Including 22 Harmful Components in E-Cigarettes
South Korea Implements Public Tobacco Harmfulness Management Program, Including 22 Harmful Components in E-Cigarettes
South Korea’s Ministry of Health and Welfare and the Ministry of Food and Drug Safety convened the first 2025 Tobacco Harmfulness Management Policy Committee, finalizing new lists of harmful substances for cigarettes, heated tobacco products, and liquid e-cigarettes to be publicly disclosed from next year.
Nov.14 by 2FIRSTS.ai
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
The U.S. Food and Drug Administration has confirmed that six on! PLUS nicotine pouch products have received Marketing Granted Orders (MGO) through the PMTA pathway. The authorizations were completed under the agency’s nicotine pouch review pilot program in “record time,” with the FDA citing lower levels of harmful constituents while stressing that the decision applies only to the specified products and does not mean they are safe or FDA approved.
Regulations
Dec.20